Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Borderline ovarian tumors in Denmark 1997-2018: Time trends in incidence by histology, age and educational level

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Low-dose aspirin use and risk of head and neck cancer-A Danish nationwide case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Endometrial cancer risk after fertility treatment: a population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Katharine K Brieger
  • Siri Peterson
  • Alice W Lee
  • Bhramar Mukherjee
  • Kelly M Bakulski
  • Aliya Alimujiang
  • Hoda Anton-Culver
  • Michael S Anglesio
  • Elisa V Bandera
  • Andrew Berchuck
  • David D L Bowtell
  • Georgia Chenevix-Trench
  • Kathleen R Cho
  • Daniel W Cramer
  • Anna DeFazio
  • Jennifer A Doherty
  • Renée T Fortner
  • Dale W Garsed
  • Simon A Gayther
  • Aleksandra Gentry-Maharaj
  • Ellen L Goode
  • Marc T Goodman
  • Holly R Harris
  • Estrid Høgdall
  • David G Huntsman
  • Hui Shen
  • Sharon E Johnatty
  • Susan J Jordan
  • Susanne K Kjaer
  • Jolanta Kupryjanczyk
  • Diether Lambrechts
  • Karen McLean
  • Usha Menon
  • Francesmary Modugno
  • Kirsten Moysich
  • Roberta Ness
  • Susan J Ramus
  • Jean Richardson
  • Harvey Risch
  • Mary Anne Rossing
  • Britton Trabert
  • Nicolas Wentzensen
  • Argyrios Ziogas
  • Kathryn L Terry
  • Anna H Wu
  • Gillian E Hanley
  • Paul Pharoah
  • Penelope M Webb
  • Malcolm C Pike
  • Celeste Leigh Pearce
  • Ovarian Cancer Association Consortium
View graph of relations

PURPOSE: Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival.

METHODS: Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery.

RESULTS: Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival.

CONCLUSIONS: Pre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.

Original languageEnglish
JournalGynecologic Oncology
Volume158
Issue number3
Pages (from-to)702-709
Number of pages8
ISSN0090-8258
DOIs
Publication statusPublished - Sep 2020

ID: 61556019